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A B S T R A C T
Background
Patient adherence to medications, particularly for conditions requiring prolonged treatment such as tuberculosis (TB), is frequently less
than ideal and can result in poor treatment outcomes. Material incentives to reward good behaviour and enablers to remove economic
barriers to accessing care are sometimes given in the form of cash, vouchers, or food to improve adherence.
Objectives
To evaluate the effects of material incentives and enablers in patients undergoing diagnostic testing, or receiving prophylactic or curative
therapy, for TB.
Search methods
We undertook a comprehensive search of the Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of
Controlled Trials (CENTRAL); MEDLINE; EMBASE; LILACS; Science Citation Index; and reference lists of relevant publications
up to 5 June 2015.
Selection criteria
Randomized controlled trials of material incentives in patients being investigated for TB, or on treatment for latent or active TB.
Data collection and analysis
At least two review authors independently screened and selected studies, extracted data, and assessed the risk of bias in the included
trials. We compared the effects of interventions using risk ratios (RR), and presented RRs with 95% confidence intervals (CI). The
quality of the evidence was assessed using GRADE.
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Main results
We identified 12 eligible trials. Ten were conducted in the USA: in adolescents (one trial), in injection drug or cocaine users (four trials),
in homeless adults (three trials), and in prisoners (two trials). The remaining two trials, in general adult populations, were conducted
in Timor-Leste and South Africa.
Sustained incentive programmes
Only two trials have assessed whether material incentives and enablers can improve long-term adherence and completion of treatment
for active TB, and neither demonstrated a clear benefit (RR 1.04, 95% CI 0.97 to 1.14; two trials, 4356 participants; low quality
evidence). In one trial, the incentive, given as a daily hot meal, was not well received by the population due to the inconvenience of
attending the clinic at midday, whilst in the other trial, nurses distributing the vouchers chose to “ration” their distribution among
eligible patients, giving only to those whom they felt were most deprived.
Three trials assessed the effects of material incentives and enablers on completion of TB prophylaxis with mixed results (low quality
evidence). A large effect was seen with regular cash incentives given to drug users at each clinic visit in a setting with extremely low
treatment completion in the control group (treatment completion 52.8% intervention versus 3.6% control; RR 14.53, 95% CI 3.64
to 57.98; one trial, 108 participants), but no effects were seen in one trial assessing a cash incentive for recently released prisoners (373
participants), or another trial assessing material incentives offered by parents to teenagers (388 participants).
Single once-only incentives
However in specific populations, such as recently released prisoners, drug users, and the homeless, trials show that material incentives
probably do improve one-off clinic re-attendance for initiation or continuation of anti-TB prophylaxis (RR 1.58, 95% CI 1.27 to 1.96;
three trials, 595 participants; moderate quality evidence), and may increase the return rate for reading of tuberculin skin test results (RR
2.16, 95% CI 1.41 to 3.29; two trials, 1371 participants; low quality evidence).
Comparison of different types of incentives
Single trials in specific sub-populations suggest that an immediate cash incentive may be more effective than delaying the incentive
until completion of treatment (RR 1.11, 95% CI 0.98 to 1.24; one trial, 300 participants; low quality evidence), cash incentives may
be more effective than non-cash incentives (completion of TB prophylaxis: RR 1.26, 95% CI 1.02 to 1.56; one trial, 141 participants;
low quality evidence; return for skin test reading: RR 1.13, 95% CI 1.07 to 1.19; one trial, 652 participants; low quality evidence); and
higher cash incentives may be more effective than lower cash incentives (RR 1.08, 95% CI 1.01 to 1.16; one trial, 404 participants;
low quality evidence).
Authors’ conclusions
Material incentives and enablers may have some positive short term effects on clinic attendance, particularly for marginal populations
such as drug users, recently released prisoners, and the homeless, but there is currently insufficient evidence to know if they can improve
long term adherence to TB treatment.
P L A I N L A N G U A G E S U M M A R Y
Incentives and enablers for improving patient adherence to tuberculosis diagnosis, prophylaxis, and treatment
Cochrane researchers conducted a review of the effects of material (economic) incentives or enablers on the adherence and outcomes of
patients being tested or treated for latent or active tuberculosis (TB). After searching up to 5 June 2015 for relevant trials, they included
12 randomized controlled trials in this Cochrane review.
What are material incentives and enablers and how might they improve patient care?
Material incentives and enablers are economic interventions which may be given to patients to reward healthy behaviour (incentives)
or remove economic barriers to accessing healthcare (enablers). Incentives and enablers may be given directly as cash or vouchers, or
indirectly in the provision of a service for which the patient might otherwise have to pay (like transport to a health facility).
What the research says
Material incentives and enablers may have little or no effect in improving the outcomes of patients on treatment for active TB (low
quality evidence), but further trials of alternative incentives and enablers are needed.
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Material incentives and enablers may have some effects on completion of prophylaxis for latent TB in some circumstances but trial
results were mixed, with one trial showing a large effect, and two trials showing no effect (low quality evidence).
One-off material incentives and enablers probably improve rates of return to a single clinic appointment for patients starting or
continuing prophylaxis for TB (moderate quality evidence) and may improve the rate of return to the clinic for the reading of diagnostic
tests for TB (low quality evidence).
Thus although material incentives and enablers may improve some patients’ attendance at the clinic in the short term, more research
is needed to determine if they have an important positive effect in patients on long term treatment for TB.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Material incentives compared to routine care for improving patient adherence to TB management
Patient or population: Recipients of TB control services
Settings: Middle-income and high-income country sett ings (South Af rica, Timore-Leste, USA)
Intervention: Material incent ives (such as cash, grocery vouchers, or food)
Comparison: Routine care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(trials)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Routine care Material incentives
Sustained incentive programme
Cure or completion of treat-
ment for active TB
721 per 1000 750 per 1000
(620 to 807)
RR 1.04
(0.97 to 1.13)
4356
(2 trials)
⊕⊕©©
low1
Completion of TB prophy-
laxis
- - Not pooled 869
(3 trials)
⊕⊕©©
low2,3
Single once-only incentive
Return to clinic to start or
continue treatment
249 per 1000 393 per 1000
(316 to 488)
RR 1.58
(1.27 to 1.96)
595
(3 trials)
⊕⊕⊕©
moderate4
Return for tuberculin skin
test reading
441 per 1000 953 per 1000
(622 to 1000)
RR 2.16
(1.41 to 3.29)
1371
(2 trials)
⊕⊕©©
low5,6
The assumed risk is taken f rom the control groups in the trials. The corresponding risk (and its 95%CI) is based on the assumed risk in the comparison group and the relative
effect of the intervent ion (and its 95% CI).
CI: conf idence interval; RR: risk rat io.
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
1Downgraded by 2 for indirectness: these two trials evaluated specif ic intervent ions amongst specif ic populat ions, and
problems with the acceptability and implementat ion of the intervent ion in both trials lim it the generalizability of this f inding
of no ef fect.
2Downgraded by 1 for indirectness: these trials were conducted in specif ic subpopulat ions f rom the USA (drug users, recent ly
released prisoners, and adolescents), and the result may not be applicable in other sett ings.
3Downgraded by 1 for inconsistency: two studies found no suggest ion of a benef it with the incent ive, and one study found a
clinically and stat ist ically signif icant benef it in drug users in a sett ing where adherence without incent ives was very low.
4Downgraded by 1 for indirectness: these trials were conducted in specif ic subpopulat ions f rom the USA (the homeless or
recent ly released prisoners), and the result may not be applicable in other sett ings.
5Downgraded by 1 for risk of bias: neither study adequately described the method of randomizat ion.
6Downgraded by 1 for indirectness: these trials were conducted in specif ic subpopulat ions f rom the USA (drug users), and
the result may not be applicable in other sett ings.
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B A C K G R O U N D
Description of the condition
Tuberculosis (TB) is an infectious disease caused by the bacterium
Mycobacterium tuberculosis, which spreads from person to person
by inhalation of respiratory droplets. Although the global inci-
dence of TB is falling, the burden of disease is still high, especially
in low- and middle-income countries (LMICs) where it is asso-
ciated with poverty (WHO 2013). Impaired immunity, due to
co-infection with the human immuno-deficiency virus (HIV) or
poor nutrition, plays an important role in many infections (WHO
2009a; WHO 2013).
Following the initial infection, most people do not develop symp-
toms as M. tuberculosis bacteria are completely controlled by the
immune system, and lie dormant in a state known as ’latent TB’.
Active TB, where the bacterium is no longer controlled by the im-
mune system, can occur at any time following infection and most
commonly affects the lungs, causing a chronic cough (which acts
to spread the disease), loss of weight, loss of appetite, and general
malaise (Harries 2006).
The most widely used method of diagnosing latent TB is the tu-
berculin test (also known as the Mantoux test), which involves in-
jecting a small amount of a purifiedM. tuberculosis protein under
the skin, usually of the forearm. If the person has previously been
exposed to TB, a small swelling occurs due to a localized immune
response, and the size of this response is measured 48 to 72 hours
later (CDC 2010). Treatment of latent TB, often called TB pro-
phylaxis, aims to prevent the later development of active disease,
and reduce transmission.
Effective treatment for both active and latent TB requires regular
medication to be taken for six to 12 months, and non-adherence
to this difficult and prolonged schedule is the most common cause
of treatment failure (Narayanan 2003; Volmink 2000). Non-ad-
herence, with prolonged infectiousness, constitutes a health risk to
close family and community contacts, and can lead to the devel-
opment of drug-resistant organisms which are more difficult and
more expensive to treat (Lam 2002).
Adherence is not the sole responsibility of the patient, nor of the
health system, but some combination of the two (Garner 2007),
and consequently interventions aimed at reducing non-adherence
may need to target both. These interventions may be classified as:
technical (making the medications simpler to take, such as reduc-
ing doses and personalising packaging); behavioural (establishing
a pattern of behaviour through stimuli or positive reinforcement);
educational (improving patients’ capacity tomanage their diseases,
often through a cognitive didactic approach); structural (improv-
ing the accessibility and acceptability of TB programmes); or com-
plex (a combination of these) (Haynes 2008; Munro 2007; van
Dulmen 2007; WHO 2003c). A review of direct observation has
been completed indicating little added effect of direct observation
(Karumbi 2015), and a review of patient reminders and prompts is
also available showing mixed effects (Liu 2014). A further review
found that patient education may improve completion of treat-
ment for latent TB (no trials were found investigating the effect
of patient education for active TB) (M’Imunya 2012).
Description of the intervention
Incentives and enablers are interventions targeted at the patient
which seek to either promote or assist improved adherence (WHO
2003a; WHO 2003b; WHO 2003c). They may be given directly
as cash or vouchers for groceries, or indirectly as the provision of
a service for which the patient would otherwise have had to pay
(for example, transport to and from the clinic).
A recent overview of reviews found that material incentives im-
proved adherence and outcomes for a number of health problems,
and also increased the utilisation of health services for prevention
programmes (Sutherland 2008). Conditional cash transfers, used
primarily in Latin America, are essentially material incentives used
on a large scale to promote healthy behaviour in poor families and
individuals (Lagarde 2007). They have been particularly success-
ful in promoting the use of health services and in improving nu-
tritional and anthropometric outcomes in certain groups (Lagarde
2007).
How the intervention might work
Incentives are based on behavioural theories of reward for ’good’
behaviour (van Dulmen 2007), and may be defined as “any fi-
nancial or material reward that patients and/or providers receive,
conditional on their explicitly measured performance or behavior”
(Beith 2007). Alternatively, ’enablers’ assist patients to adhere by
overcoming the financial barriers to treatment. In a recent quali-
tative review, economic constraints due to absences from work to
attend appointments, or the direct and indirect costs of accessing
treatment, were commonly cited by patients as important barriers
to completing TB treatment (Munro 2007).
As well as potential benefits, the use of material incentives and
enablers may also have unintentional negative consequences. Pa-
tientswho receive incentives to adhere to one health behaviourmay
be reluctant to adhere to others if they are not also accompanied
by incentives (Malotte 1999). This might be especially important
where incentives are offered in one of several possible stages in a
multi-stage treatment process such as screening for and treating
TB. Further possible negative effects include: resentment in pa-
tients who do not receive the incentive (Malotte 2001); fraud and
corruption, with patients manipulating the incentive system to
gain more; or the creation of ’ghost’ patients allowing health staff
to steal incentives from the system (White 1998); or the ’perverse
incentive’ effect, where the incentive induces exactly the oppo-
site behaviour to that intended, ie patients who want to continue
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receiving the incentive may deliberately not take medications in
order to remain ill.
Why it is important to do this review
In light of the increased risk of TB posed byHIV infection (WHO
2013), and the development of epidemics of drug-resistant forms
of TB (Wells 2007; Yang 2011), efforts to help patients complete
therapy are of paramount importance. If material incentives and
enablers do improve adherence rates amongst patients with TB,
they should be used far more widely than they are currently.
O B J E C T I V E S
To evaluate the effects of material incentives and enablers given to
patients undergoing diagnostic testing for TB, or receiving drug
therapy to prevent or cure TB.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs), where the unit of allocation
is either an individual or cluster.
Types of participants
• People receiving curative treatment for active TB: smear
positive cases, smear negative cases, new cases, and re-treatment
cases;
• People receiving preventive therapy for latent TB: patients
at risk of developing active TB and taking anti-TB
chemoprophylaxis (ie isoniazid preventive therapy);
• People suspected of TB undergoing, and collecting results
of, diagnostic tests: diagnosis of TB infection (using tuberculin
skin tests) and disease (using sputum microscopy and culture)
often requires the patient to return to the health facility a few
days after the test is performed to receive the results. Incentives
have been used to encourage patients to do this.
Types of interventions
Intervention
Interventions included any form of material inducement to return
for TB test results, or adhere to or complete anti-TB preventive
or curative treatment. These may have been direct such as cash
or vouchers for groceries, or indirect such as the provision of a
service for which the patient would otherwise have had to pay (for
example, transport to and from the clinic). We did not consider
non-material incentives, such as praise from a health worker, in
this Cochrane Review, because their economic value is difficult to
quantify and the form of the incentive is difficult to standardize.
In those trials where incentives were combined with other inter-
ventions, studies were only eligible for inclusion in a meta-anal-
ysis if disaggregation of the effect of the incentive was possible.
Other interventions that could be combined with incentives in-
clude health information and education, and increased access to
health workers through home visits, or additional appointments.
We only included trials if the standard TB curative or preventive
treatment was the same across the control and treatment arms.
Control
Controls were those patients receiving standard TB treatment or
preventive treatment, or undergoing testing for suspectedTB, who
had no incentive or an alternative incentive or intervention.
Types of outcome measures
Primary outcomes
For treatment of active TB: Cure or completion of treatment,
or both, using the following World Health Organization (WHO)
definitions (WHO 2009b):
• Cured: a patient who was initially smear-positive and who
was smear negative in the last month of treatment and on at least
one previous occasion;
• Completed treatment: a patient who completed the course
of treatment as prescribed by the health worker;
• Successfully treated: a patient who was cured or who
completed treatment (WHO 2009b).
For prophylaxis: cases of active TB; completion of prophylactic
treatment.
For diagnostics: number returning to collect test results within
the appropriate time frame for that test.
Secondary outcomes
Appointment keeping, presence of urinary markers, and certifica-
tion by direct observation of treatment.
Adverse events
Adverse events reported in trials, such as expenditure of cash or
vouchers on unhealthy items. The latter were defined as commodi-
ties that undermine the patient’s chance of cure, such as tobacco
products or alcohol.
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Costs
Cost effectiveness of the intervention; where costs include the
direct and indirect costs incurred by patients, and costs to the
health system of providing and administering the incentives.
Search methods for identification of studies
We attempted to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
For this review update we searched the following databases using
the search terms and strategy described inTable 1: Cochrane Infec-
tiousDiseasesGroupSpecializedRegister (5 June 2015);Cochrane
Central Register of Controlled Trials (CENTRAL: 5 June 2015);
MEDLINE (1966 to 5 June 2015); EMBASE (1974 to 5 June
2015); LILACS (1982 to 5 June 2015); andScienceCitation Index
(EXPANDED) and Social Sciences Citation index (SSCI) (1956
to 5 June 2015).
We also searched the metaRegister of Controlled Trials (mRCT)
using ’tuberculosis’, ’incentive’, ’cash transfer’, ’adherence’, ’com-
pliance’, and ’concordance’ as search terms (1998 to 5 June 2015).
In addition, we searched the WHO International Clinical Trials
Registry Platform (http://www.who.int/ictrp/search/en/) for on-
going trials (5 June 2015).
This is the same search strategy and the same databases that were
used for the original review, Lutge 2012.
Searching other resources
Researchers and organizations
We contacted researchers and other experts in the field of TB and
adherence research for unpublished and ongoing trials.
Reference lists
We checked the reference lists of related reviews (Garner 2007;
Haynes 2008; Lagarde 2007; Sutherland 2008; Volmink 2000)
and all full-text articles reviewed for inclusion in this review.
Data collection and analysis
Selection of studies
For the original 2012 review, Lutge 2012, Elizabeth Lutge (EL)
and Stephen Knight (SK) independently screened all citations and
abstracts identified by the search strategy for potentially eligible
studies (Lutge 2012). For this review update, EL and Charles Shey
Wiysonge (CSW) independently performed screening and study
selection. Two review authors independently assessed the full text
articles of potentially relevant studies using the pre-specified trial
inclusion criteria. We resolved any disagreements by discussion
and consensus. When a disagreement could not be resolved we
sought arbitration from a third review author; CSW in the case
of the original Cochrane review and Jimmy Volmink (JV) for
both the original, Lutge 2012, and this Cochrane review update.
We excluded studies that did not meet the inclusion criteria and
documented the reasons for exclusion in the ’Characteristics of
excluded studies’ table.
As EL is the author of a trial included in this Cochrane review
update, two review authors who were not involved with this trial
(David Sinclair (DS) and CSW) independently applied the inclu-
sion criteria, assessed risk of bias, and performed data extraction
of this trial. Two Cochrane Editors provided oversight.
Data extraction and management
In both the original review and its update, EL and CSW indepen-
dently extracted information from the selected trial reports using
a pre-designed data extraction form on study methods used, par-
ticipant characteristics, interventions, and outcomes. For all out-
comes, we extracted the number of participants randomized and
the number analysed. For each study, we extracted the number
of participants with an outcome of interest in each group as well
as the number of participants randomized to each group, and the
number analysed.
We resolved any disagreements through discussion and consensus
between EL and CSW initially, and with SK or JV if the disagree-
ment was not resolved.
Assessment of risk of bias in included studies
EL, CSW, and DS independently assessed the risk of bias in
each included trial using Cochrane’s ’Risk of bias’ assessment tool
(Higgins 2011), in line with the Cochrane policy on trialists who
are also review authors (Kliner 2014).We followed the guidance to
assess whether adequate steps were taken to reduce the risk of bias
across six specific domains, namely: random sequence generation;
allocation concealment; blinding of participants, personnel, and
outcome assessment; incomplete outcome data; selective outcome
reporting; and ’other issues’. For each included trial, we indepen-
dently described what the trial authors reported that they did for
each domain and then made a decision relating to the risk of bias
for that domain by assigning a judgement of either ’low’, ’high’,
or ’unclear’ risk of bias. EL, CSW, and DS compared the results
of their independent ’Risk of bias’ assessments and resolved any
discrepancies by discussion and consensus. A fourth review author
(JV) resolved any differences in opinion.
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Assessment of reporting biases
If at least 10 trials were included in the meta-analysis for any out-
come, we would have evaluated the likelihood of publication bias
and other sources of bias by examining the degree of asymmetry
of funnel plots. We chose this number because it has been shown
that when there are fewer than 10 studies in a meta-analysis the
power of funnel plot asymmetry tests is too low to distinguish
chance from real asymmetry (Higgins 2011).
Data synthesis
We analysed data using Review Manager (RevMan). We analysed
trial participants in groups to which they were randomized, re-
gardless of how much of the intended intervention they actually
received.
All studies reported only dichotomous data, so we have expressed
study results as the risk ratio (RR) with its 95% confidence inter-
vals (CI) for each outcome. We used the fixed-effect model for the
primary analysis. When significant statistical heterogeneity was
present and it was appropriate to combine the data, we used the
random-effects model.We stratified analyses according to the type
of incentive and control intervention, that is, incentive versus rou-
tine care, immediate versus deferred incentive, cash versus non-
cash incentive, and incentive versus any other intervention.
In addition, we used theGRADE approach to summarise the qual-
ity of the evidence on the effects of material incentives on each
outcome (Guyatt 2008). In theGRADE system, randomized trials
without important limitations constitute high quality evidence.
However, the system considers five factors that can lower the qual-
ity of the evidence: study limitations; inconsistent results across
studies; indirectness of the evidence; imprecision; and publication
bias. Overall, the GRADE system classifies research evidence into
four categories (high, moderate, low, or very low quality). High
quality evidence implies that we “are very confident that the true
effect lies close to that of the estimate of the effect”, while very
low quality evidence implies that the “true effect is likely to be
substantially different from the estimate of effect” found in the
review (Balshem 2011).
Subgroup analysis and investigation of heterogeneity
Wedetermined the presence of statistical heterogeneity across trials
by visually inspecting the forest plots to check for overlapping
CIs and by means of the Chi² test for heterogeneity with a P
value of < 0.10 indicating statistical significance. Furthermore,
we use the I² statistic to quantify the amount of heterogeneity as
either low (I² statistic value ≤ 25%), moderate (I² statistic value
between 25% and 75%), or high (I² statistic value of ≥ 75%).
If we had at least 10 studies in any meta-analysis that showed
significant statistical heterogeneity, we would have explored the
possible sources of heterogeneity by performing subgroup analyses;
with subgroups defined by age, gender, socioeconomic status, and
risk of bias (low versus high/unclear).
R E S U L T S
Description of studies
For Lutge 2012, we obtained 733 titles and abstracts from the elec-
tronic search of databases, and no additional articles from contact-
ing researchers or screening reference lists. After removal of dupli-
cates, 225 records remained. Following discussion and consensus,
we obtained 21 potentially eligible articles. Eleven RCTs met our
inclusion criteria (Chaisson 2001; Malotte 1998; Malotte 1999;
Malotte 2001; Martins 2009; Morisky 2001; Pilote 1996; Tulsky
2000; Tulsky 2004; White 1998; White 2002). The final article,
Kominski 2007, was a cost-effectiveness analysis of an included
study (Morisky 2001).
In the 2014 update to the review, we obtained five records from
the searches. We screened the abstracts of theses publications and
deemed three irrelevant (onewas a report of an education interven-
tion and two were reports of text messaging interventions for im-
proving TB treatment adherence). Two full articles were retrieved
(Gärden 2013; Lutge 2013).We excluded Gärden 2013 because it
was not a RCT; it used an historical control group as comparator
(Gärden 2013). We included the second potentially eligible study,
Lutge 2013, in this review. The search conducted in 2015 yielded
11 records, seven published articles, and four ongoing studies. Of
the seven published articles, five were clearly irrelevant to this re-
view and were excluded. One of the remaining two articles re-
ported a qualitative process evaluation of an included study (Lutge
2013). The other article reported data from an observational co-
hort study (Chua 2015), and excluded because it was not a RCT.
All four ongoing studies were found to be irrelevant to the review
and discarded.
The search and selection of studies for the original review, Lutge
2012, and its update are shown in Figure 1.
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Figure 1. PRISMA diagram showing the search and selection of studies
Included studies
The trials identified and included in this review all randomized
individual participants and reported only dichotomous outcomes.
Ten of the 12 included trials were conducted in the USA, and only
two are from low- and middle-income countries (LMICs) (Lutge
2013: South Africa; Martins 2009: Timor-Leste).
Studies varied in size from 79 to 4091 participants, with a mean of
735 participants, and most studies focused on very specific patient
subgroups. Four studies were conducted among injection drug
or cocaine users (Malotte 1998; Malotte 1999; Chaisson 2001;
Malotte 2001), three among homeless or marginally housed adults
(Pilote 1996; Tulsky 2000; Tulsky 2004), two studies in prisoners
(White 1998; White 2002), and one assessed incentives given to
adolescents aged 11 to 19 years (Morisky 2001). Only two studies
involved members of the general adult population with TB (Lutge
2013; Martins 2009).
The studies assessed adherence to different stages of TB man-
agement. Some investigated the use of incentives in improving
return for reading of tuberculin skin test results (Malotte 1998;
Malotte 1999) while others focused on improving attendance at
the clinic for initiation of treatment (Pilote 1996), adherence to
preventive TB treatment (Chaisson 2001; Malotte 2001; Morisky
2001; White 1998; White 2002; Tulsky 2000; Tulsky 2004) and
two looked at adherence to treatment for active TB (Lutge 2013;
Martins 2009).
The trials investigated various types of incentives, and several trials
had multiple study arms receiving different forms of both mate-
rial and non-material incentives. Eight studies included a study
arm given cash in values of USD 5 or USD 10 (Chaisson 2001;
Malotte 1998; Malotte 1999; Malotte 2001; Pilote 1996; Tulsky
2000; Tulsky 2004; White 1998). Four studies gave vouchers that
could be redeemed for groceries, food, transport, meals at fast
food outlets or phone calls (Lutge 2013; Malotte 1999; Tulsky
2004; White 2002), and one study gave food as a hot daily meal
(Martins 2009). In one trial, adolescent patients negotiated the
incentive they received from their parents (Morisky 2001). Com-
mon choices included special meals at home, going to a movie, or
renting a video.
These material incentives were compared with routine care, and in
multi-arm trials also with motivational education (Malotte 1998;
Malotte 1999), peer counselling (Morisky 2001; Pilote 1996;
Tulsky 2000), and standardized education sessions (White 1998;
White 2002). In addition, one study compared different levels
of incentive (Malotte 1998), one study compared an immediate
incentive, given monthly throughout treatment, with a lump sum
given on completion (Chaisson 2001), and two studies compared
different forms of incentive (Malotte 1999; Tulsky 2004).
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Excluded studies
We excluded trials for the following reasons: patients in both
trial arms were given the same incentive (Nyamathi 2006); quasi-
randomized with randomization done either by day of the week
(Cheng 1997) or by the last digits in the participants’ clinic record
numbers (Morisky 1990); cross sectional studies where one group
was given the incentive and the other was not (Cantalice Filho
2009; FitzGerald 1999; Yao 2008); or the main intervention was
community health-worker delivered TB treatment combined with
food supplements (Jahnavi 2010). In this review update, we ex-
cluded one new potentially eligible study because the control was
an historical group of patients on treatment for TB (Gärden 2013),
and another study because the intervention was not randomized
(Chua 2015).
Risk of bias in included studies
We have summarized our ’Risk of bias’ judgements for each in-
cluded trial in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We considered the generation of the randomization sequence ad-
equate in nine trials (Chaisson 2001; Lutge 2013; Malotte 2001;
Martins 2009; Pilote 1996; Tulsky 2000; Tulsky 2004; White
1998; White 2002) and unclear risk in the remainder (Malotte
1998; Malotte 1999; Morisky 2001). Allocation concealment was
judged to be adequate in five trials (Lutge 2013; Malotte 2001;
Martins 2009; White 1998; White 2002) and unclear risk in the
rest.
Blinding
Three trials had adequate blinding of outcome assessors (White
1998; White 2002; Tulsky 2004), Lutge 2013 had no blinding of
outcome assessors, and the remaining trials were unclear.
Incomplete outcome data
All the included trials addressed incomplete outcome data ade-
quately.
Selective reporting
It was unclear to us whether or not 11 of the 12 included RCTs
were free of selective outcome reporting since the study proto-
cols were unavailable and there was no earlier methods paper list-
ing the pre-specified outcomes for any of the trials. The one trial
which was prospectively registered prior to commencement (Cur-
rent Controlled Trials ISRCTN50689131) was free of selective
reporting (Lutge 2013).
Other potential sources of bias
Tulsky 2004 compared the effects of cash and non-cash incentives
among homeless adults on adherence to treatment for latent TB
infection as well as the length of time needed to look for partic-
ipants who missed their dose of medications. Although the par-
ticipants were described as homeless, the study groups were not
the same with respect to their primary housing in the year prior
to the study. In the cash incentive arm, 23% had lived in a shelter
or on the street, whilst 41% of the non-cash incentive arm had
done so (Tulsky 2004). This baseline difference had the potential
to introduce systematic differences in study outcomes.
The conduct of the two trials amongst patients on treatment for
active TB were affected by contextual issues that had important
implications for their results (Lutge 2013;Martins 2009). InMar-
tin’s trial, two important factors affected the conduct of the trial
and undermined the potential effectiveness of the intervention.
The first was civil conflict that arose during the last few months
of the trial, resulting in the displacement of approximately 70%
of the local population, and dramatically increasing the rate of
default from treatment (Martins 2009). The second factor was the
timing of the provision of meals to patients in the intervention
group. Many patients found the provision of meals, together with
treatment, at midday inconvenient, and this may have become a
barrier to adherence to treatment (Martins 2009). In Lutge 2013,
fidelity to the intervention was poor, with only 31.5% of patients
receiving their vouchers for most of their treatment. More than a
third (36.2%) of eligible patients did not receive a voucher at all
and the remainder received vouchers for between one and three
months of treatment. This low fidelity was attributed largely to
nurses’ rationing of the vouchers to those whom they felt were
more deprived and therefore more deserving (Lutge 2013). It is
important that such contextual issues be considered in further tri-
als of this nature. In the very environments where extensive poverty
or conflicts prevail and TB is likely to be more prevalent, contex-
tual issues may profoundly affect the conduct and the results of
the trials.
Effects of interventions
See: Summary of findings for the main comparison Summary
of findings table 1
Incentives versus routine care
Completion of treatment for active TB
Two trials examined the effect of material incentives in patients
with active TB. One trial evaluated incentives given as food (in
the form of hot meals at the clinic during the intensive phase of
treatment followed by monthly food parcels) compared to usual
care with nutritional advice (Martins 2009), and the second trial
compared vouchers, redeemable for food and household goods,
with usual care alone (Lutge 2013). Neither trial found statisti-
cally significant differences in treatment completion rates between
participants given incentives and those receiving usual care (RR
1.04, 95% CI 0.97 to 1.14; two trials, 4356 participants; Analysis
1.1).
Completion of TB prophylaxis
Three studies from the USA examined the effect of incentives on
completion of TB prophylaxis. Malotte 2001 gave a USD 5 cash
incentive to drug users on attendance for twice weekly directly
observed treatment, Morisky 2001 established an incentive agree-
ment between adolescents aged between 11 to 19 years and their
parents, where parents provided cash or treats at various stages
in the treatment process, and White 2002 gave recently released
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prisoners transportation vouchers worth USD 25 upon first pre-
sentation at a TB clinic.
Malotte 2001 showed large effects with incentives, with over half
the 53 patients completing treatmentwith an incentive, contrasted
with very low completion in the control (2/55). In Morisky 2001,
completion of treatment was better in the control group (77.8%),
and was similar with the incentive (76.4%), while in White 2002
completion remained low in both groups despite the intervention
(13.8% control versus 14.1% intervention).
Return to clinic for initiation or continuation of TB
prophylaxis
Three studies from the USA compared material incentives with
routine care (Pilote 1996; White 1998; White 2002). Pilote 1996
gave USD5 to homeless people on return to a clinic after a positive
tuberculin skin test, White 1998 gave USD 5 when recently re-
leased prisoners attended a community clinic for continuation of
TB prophylaxis, and White 2002 gave recently released prisoners
food or transportation vouchers worth USD25 upon presentation
at a TB clinic.
Incentives improved clinic attendance for initiation or continua-
tion of treatment for latent TB infection (RR 1.58, 95% CI 1.27
to 1.96; three trials, 595 participants; Analysis 1.3). Completion
rates in the control groups varied, and this was also the case in the
intervention group, so that despite the apparent benefit in terms
of relative risk, in two trials in prisoners, attendance at clinics re-
mained lower than 25% even in the intervention groups.
Return to clinic for tuberculin skin test reading
Two studies in drug users from the USA compared material incen-
tives (USD 5 to USD 10) with routine care alone (Malotte 1998;
Malotte 1999).
Material incentives increased the proportion of people who re-
turned for reading of the tuberculin skin test (RR 2.16, 95% CI
1.41 to 3.29; two trials, 1371 participants; Analysis 1.4), both
with quantitatively important large effects.
Immediate versus deferred incentive
Completion of TB prophylaxis
One study among drug users (Chaisson 2001), compared the ef-
fects of an immediate incentive (USD 10 for each monthly ap-
pointment attended) with the promise of a deferred lump sum
(USD 10 for each appointment attended) on completion of TB
prophylaxis.
The participants who received the immediate incentives com-
pleted treatment more often than those whose incentives were de-
ferred (83% versus 75%), but the difference was not statistically
significant (RR 1.11, 95% CI 0.98 to 1.24; one trial, 300 partic-
ipants; Analysis 2.1).
Cash versus non-cash incentives
Completion of TB prophylaxis
One study among homeless and marginally housed adults with la-
tent TB infection (Tulsky 2004) compared a cash incentive (USD
5), with non-cash incentives (patients could choose between fast
food or grocery store coupons, phone cards or bus tokens equiv-
alent to USD 5). The cash incentive was more effective than the
non-cash incentives (RR 1.26, 95% CI 1.02 to 1.56; one trial,
141 participants; Analysis 3.1).
Return to clinic for tuberculin skin test reading
One study amongst injection drug and crack cocaine users
(Malotte 1999), directly compared a cash incentive (USD10)with
non-cash incentives (grocery store coupons, bus tokens and fast
food coupons equivalent in value to USD 10).
The cash incentive was significantly more effective at increasing
return for reading of tuberculin skin tests than any of the non-
cash incentives (RR 1.13, 95% CI 1.07 to 1.19; one trial, 652
participants; Analysis 3.2).
Different values of cash incentive
Return to clinic for tuberculin skin test reading
One trial, Malotte 1998, also compared different values of cash
incentive (USD 10 versus USD 5).
The USD 10 incentive significantly increased the proportion of
patients returning to clinic to collect their TB test result compared
to the USD 5 incentive (RR 1.08, 95% CI 1.01 to 1.16; one trial,
404 participants; Analysis 5.1).
Incentives versus any other intervention
Completion of TB prophylaxis
Three trials also used peer counselling or education sessions to
promote completion of TB prophylaxis: one among jail inmates
(White 2002), one amongst homeless adults (Tulsky 2000), and
one among adolescents (Morisky 2001). There was no significant
difference between material incentives and education or coun-
selling (RR 1.04, 95% CI 0.59 to 1.83; 3 trials, 837 participants;
Analysis 4.1).
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Return to clinic for initiation or continuation of TB
prophylaxis
Two trials assessing return to clinic for TB prophylaxis compared
material incentives with education or counselling. Both are from
the USA; Pilote 1996 used peer counsellors to encourage home-
less men and women to attend clinic after a positive test result,
and White 2002 gave education sessions every two weeks to jail
inmates to encourage attendance at a community clinic upon re-
lease.There was no significant difference between material incen-
tives and education or peer counselling (RR 1.10, 95% CI 0.92
to 1.31; two trials, 535 participants; Analysis 4.2).
Return to clinic for tuberculin skin test reading
The two trials among drug users in the USA (Malotte 1998;
Malotte 1999), also had a treatment arm which received 5 to 10
minutes of motivational education .
Thematerial incentives (USD5 toUSD10) significantly increased
the rate of return for tuberculin skin test reading compared to
motivational education alone (RR 2.16, 95%CI 1.56 to 3.00; two
trials, 1366 participants; Analysis 4.3).
Potential effect modifiers
The most commonly reported potential effect modifier was edu-
cational status. Six trials assessed this and no effect on outcomes
was noted (Malotte 1998; Malotte 1999; Malotte 2001; Pilote
1996; Tulsky 2004;White 2002). In one trial, it was noted that the
following groups had significantly lower treatment success rates:
patients who were unemployed (compared to those who were
employed); children older than 13 years (compared to children
younger than 13 years); men (compared to women); and patients
with smear negative TB (compared to patients with smear positive
TB) (Lutge 2013).
None of the studies reported their results subgrouped by HIV
status. In three studies it was noted thatHIV positive patients were
included (Malotte 1998;Malotte 1999;Malotte 2001), and in one
study itwas noted that the population fromwhich the study sample
was drawn had a generally low HIV prevalence (Martins 2009).
In one trial, missing data on HIV status precluded its analysis
(Lutge 2013) and in a further three trials HIV positive patients
were actively excluded (Tulsky 2000; Tulsky 2004; White 2002).
Adverse events
Although adverse events due to the anti-TB drugs administered
(such as isoniazid) were noted in some trials, adverse effects of the
incentives and enablers themselves were only investigated in one
study (Lutge 2013). Lutge 2013 recorded very few incidents of
theft of vouchers, andnoobvious perverse incentive effect. Patients
were not inclined to stop taking their TB treatment, in order to
remain ill and therefore continue receiving their vouchers.
Cost effectiveness
We found one paper reporting a cost analysis, Kominski 2007,
which related to an included trial (Morisky 2001). This trial in-
volved the administration of an incentive to adolescents with la-
tent TB (in the form of a “contingency contract” with their par-
ents). In a second trial, the costs of providing the intervention were
described as effectively doubling the cost of treatment per patient
(Martins 2009). However, since neither of these trials demon-
strated any clinical benefit with the use of these interventions, any
further appraisal of the cost components is inappropriate.
D I S C U S S I O N
Summary of main results
Only two trials have assessed whether material incentives and en-
ablers can improve long-term adherence and completion of treat-
ment for active TB, and neither demonstrated a clear benefit (low
quality evidence).
Three trials assessed the effects of material incentives on comple-
tion of TB prophylaxis with mixed results (low quality evidence).
A large effect was seen with regular cash incentives given to drug
users at each clinic visit in a setting with extremely low treatment
completion in the control group. A second trial in prisoners found
no effect with a cash incentive at the start of treatment, and a third
trial from a setting with reasonably high treatment completion
among teenagers found that material incentives offered by parents
did not improve treatment completion compared to parental su-
pervision alone.
However in specific populations, such as recently released prison-
ers, drug users, and the homeless, trials show that material incen-
tives probably do improve one off clinic re-attendance for initia-
tion or continuation of anti-TB prophylaxis (moderate quality ev-
idence), and may increase the return rate for reading of tuberculin
skin test results (low quality evidence).
Overall completeness and applicability of
evidence
Only two studies have evaluated the long term effects of mate-
rial incentives on TB treatment outcomes. Although both were
conducted in highly endemic settings, their findings are not eas-
ily generalized to wider populations because of specific contextual
factors affecting each trial. In one trial, the incentive, given as a
hot daily meal, was not well received by the population due to
the inconvenience of attending the clinic at midday. In addition,
conflict in the area affected clinic attendance and therefore par-
ticipation in the trial. In the second trial, the nurses distributing
the vouchers chose to “ration” their distribution among eligible
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patients and consequently decreased the power of this trial to de-
tect a statistically significant result. These factors served to reduce
the quality of the evidence presented by these trials and therefore,
although neither trial showed a benefit, other trials not affected by
such factorsmay do so. These trials demonstrate the importance of
context in the conduct of research around economic interventions
to improve TB treatment outcomes. Although relevant in all re-
search, the context in which trials of social interventions take place
may profoundly affect the trials. Trials of economic interventions
tested in different contexts may have different results, depending
on the levels of poverty, social stability, and social cohesion pre-
vailing at the time. Such factors, whilst having an important effect
on the incidence and outcomes of TB, may also have an impact
on the effectiveness of economic interventions designed to reduce
incidence and improve outcomes. Therefore the context of such
trials, and the effect of the context on the generalizability of trial
results, should be carefully considered in trial design and report-
ing.
The remaining studies were all conducted in traditionally hard
to reach or marginal populations; injecting drug users, homeless
people, prison inmates, and adolescents. It is possible that these
subpopulations have different relationships with material incen-
tives, than the general population. Economic incentives and en-
ablers may be perceived and used differently by different groups,
and although these marginalized groups are vulnerable to TB, and
therefore trials in these groups remain important, the effects of
economic interventions may be different in these groups com-
pared to the broader adult population. In addition, the trials that
tested economic incentives and enablers in marginalized groups
took place in the USA, where the context in terms of the health
services, poverty levels, social stability and social cohesion may be
different from that of LMICs, where the burden of TB is highest.
Thus the results of these trials may be applicable only in the setting
of the USA, and only to the groups in which the trials occurred.
One important consideration in extrapolating these results to other
populations is HIV. It is possible that HIV co-infection may affect
adherence to anti-TB medications, either positively (for example,
through adherence education received in the HIV programme),
or negatively (for example, because illness prevents patients from
attending the clinic, or because patients are already taking a num-
ber of medications for HIV). However, HIV was not considered
in most of these studies. Since the risk of developing TB among
patients with HIV is far higher than in those who are HIV neg-
ative (WHO 2009a), future studies on economic incentives and
enablers for TB should specifically investigate the effect of HIV
status on outcomes.
In some settings, health workers and managers may be concerned
about giving cash to patients. Indeed, this was the rationale for the
inclusion of non-cash incentives in one trial included in this review
(Malotte 1999). The reason for this concern was not described
in the trial, but could be related to the expenditure of cash on
unhealthy purchases. Vouchers for specified goods cannot be spent
on such items and in fact were demonstrated by this trial to have
a beneficial effect on return for tuberculin skin testing.
A further objection to the use of incentives may be to the ratio-
nale of ’paying the patient’ to behave in a healthy way (when it is
considered the patients’ responsibility to do so). However in poor
settings, it may be difficult, if not impossible, for the patient to
access the clinic or pay for medicines (McIntyre 2006). This ac-
knowledgement underlies the Opportunidades Programme (now
Progressa Programme) in Mexico, where patients are assisted fi-
nancially in return for behaviours that will promote the health of
families (Lagarde 2007). This programme has been shown to have
benefits in a poor population (Lagarde 2007), as well as in groups
of vulnerable patients in wealthier settings (such as homeless peo-
ple in the USA) (Pilote 1996). Indeed, in the process evaluation
of one of the included trials, nurses responsible for administering
the vouchers perceived them to be helping needy patients, rather
than paying them to enable a certain behaviour (Lutge 2013).
Quality of the evidence
We assessed the quality of evidence in this review using GRADE
methods, and presented it in five ’Summary of findings’ tables
(Summary of findings for the main comparison; Appendix 1;
Appendix 2; Appendix 3; Appendix 4). The evidence is generally
considered to be of low or very low quality, which indicates that
further research is very likely to change these estimates of effect.
The main reason for downgrading quality was the indirectness of
the evidence, with only two trials from the general adult popula-
tion of LMICs.
Potential biases in the review process
We minimised potential biases in the review process by adhering
to Cochrane guidelines (Higgins 2011). We conducted compre-
hensive searches of both peer-reviewed and grey literature, without
limiting the searches to a specific language. Two review authors in-
dependently assessed study eligibility, extracted data, and assessed
the risk of bias in each included study.
Agreements and disagreements with other
studies or reviews
Consistent with the findings of relevant previous reviews (Haynes
2008; Lagarde 2007; Sutherland 2008), we found that material
incentives and enablers may promote the uptake of health services
in certain settings. However, to the best of our knowledge, our
review is themost comprehensive synthesis of existing evidence on
the effects of material incentives in patients undergoing diagnostic
testing for TB or receiving drug therapy to prevent or cure TB.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Material incentives may have some positive effects on adherence
in the short term, particularly for marginal populations such as
drug users, recently released prisoners, and the homeless, but there
is currently insufficient evidence to know if they can improve the
long term adherence to TB treatment.
Implications for research
Further high-quality studies will help explore and delineate the
effects and costs of incentives and enablers to improve adherence
to the long-term treatment of active TB.
Future studies should specifically investigate the role of HIV and
socioeconomic status in modifying the effects of incentives for
TB treatment. The possible adverse effects of incentives, such as
misuse of incentives, fraudulent practices, the effect of incentives
on non-recipients, and the perverse incentive effect, should also
be considered.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chaisson 2001
Methods Individually RCT, factorial design
Duration of enrolment: June 1995 to August 1997
Participants Number enrolled: 300
Inclusion criteria: injection drug users over 18 years old, with tuberculin skin test reading
of more than 5 mm induration if HIV positive or more than 10 mm if HIV negative,
on preventive treatment for TB
Exclusion criteria: evidence of active TB, history of serious adverse reaction to INH
(isoniazid) treatment, previous INH treatment for≥ 6 months, serum ALT elevated > 5
times normal levels, or HIV disease with CD4 count < 200/mm³. (Isoniazid is a standard
TB medication used for both prophylaxis and treatment of active TB)
Interventions All participants were randomly assigned to receive either:
1. A an immediate USD 10 stipend per month (for each monthly appointment
kept); or
2. A deferred amount, equal to USD 10 for each monthly appointment kept.
The immediate payment was given at the end of each month when the patient had
completed a routine assessment for adherence and drug toxicity. The deferred payment
was credited each month a patient in this group completed assessment for adherence
and toxicity, but payment was made when treatment was completed or when the patient
withdrew from the study
Each arm was on prophylaxis for TB.
Outcomes Completion of 6 months of INH preventive treatment (reporting for each of 6 monthly
visits and taking at least 80% of medication)
Notes Independent of the material incentive, all patients were randomly assigned to directly
observed preventive therapy (i.e. outreach meeting with a nurse twice a week; peer
support counselling (i.e. monthly support group meetings); or routine care (i.e. monthly
clinic visits)
Trial location: Baltimore, USA
Setting: community-based TB clinic
Source of funding: National Institute on Drug Abuse (DA 08992) and the National
Institute of Allergy and Infectious Diseases (AI 01637)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence generation performed by com-
puter algorithm.
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Chaisson 2001 (Continued)
Allocation concealment (selection bias) Unclear risk No description of allocation concealment
was given.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not known if outcome assessors were
blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Numbers presented for whole group and
each arm, intention-to-treat (ITT) analy-
sis. Withdrawals included “failure to return
(37 patients), voluntary withdrawal (4)...
and other reasons (13)”. These do not seem
to be related to the material incentives
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
Lutge 2013
Methods Cluster RCT using primary health care clinics as clusters
Duration: July 2009 to March 2010
Participants Number enrolled: 20 clinics randomized, enrolling 4091 TB patients
Inclusion criteria: all patients diagnosed with pulmonary, drug sensitive TB, and starting
TB treatment during the study period. Includes both adults and children
Exclusion criteria: none stated
Interventions Primary health care clinics were randomized to provide:
1. Standard TB care plus material incentives: A voucher valued at ZAR120
(approximately USD 15) was offered to patients by nurses every month on collection
of their TB treatment to a maximum of eight months. Patients were advised to redeem
the voucher for healthy foodstuffs but this was not monitored;
2. Standard TB care.
Outcomes Primary outcome: TB treatment success defined as cure or treatment completion
Secondary outcomes:
1. Default;
2. Treatment interrupted;
3. TB treatment failure;
4. Multi-drug resistant TB;
5. Deaths.
Notes Trial location: KwaZulu-Natal, South Africa
Setting: urban and rural primary healthcare clinics
Source of funding: Research Programme of the National Department of Health (South
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Lutge 2013 (Continued)
Africa), the Tuberculosis Control Assistance Program (TP CAP, the Netherlands), the
Wellcome Trust (UK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “The 20 study clinics were randomly se-
lected from the 26 eligible clinics stratified
by district. Within the two districts, the
study clinics were randomly assigned in a
1:1 ratio, using a randomisation list gener-
ated by the study statistician.”
Allocation concealment (selection bias) Low risk “Clinics were allocated to intervention or
control groups by the study statistician and
no changes were made to this allocation”
Personal communication with the trial au-
thor: The study statistician had no knowl-
edge of the clinic sites being randomized
and was based Cape town
Blinding (performance bias and detection
bias)
All outcomes
High risk “Because of the nature of the intervention,
no blinding was possible.”
“Data extractors were not blinded as it was
considered neither practical nor feasible to
conceal from them the intervention status
of the clinic.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk There was no loss of clusters.
Outcome data were unavailable on 0.2% of
patients in intervention clinics and 0.7%
of patients in control clinics
Selective reporting (reporting bias) Low risk No evidence of selective outcome reporting
identified.
Other bias Unclear risk Fidelity to the intervention was poor, with
only 31.5% of patients receiving their
vouchers for most of their treatment. More
than a third (36.2%) of eligible patients did
not receive a voucher at all and the remain-
der received vouchers for between 1 and 3
months of treatment. This low fidelity was
attributed largely to nurses’ rationing of the
vouchers to thosewhom they felt weremore
deprived and therefore more deserving
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Malotte 1998
Methods Individually RCT
Duration: April 1994 to August 1995
Participants Number enrolled: 1004
Inclusion criteria: injection drug and crack cocaine users, who had tuberculin skin tests
and were required to return for the reading
Exclusion criteria: none stated
Interventions Participants were divided into 6 arms, which received the following interventions:
1. 5 to 10 minute session of motivational education;
2. 5 to 10 minute session of motivational education plus USD 10 on return for
tuberculin skin test reading;
3. 5 to 10 minute session of motivational education plus USD 5 on return for
tuberculin skin test reading;
4. USD 10 on return for tuberculin skin test reading;
5. USD 5 on return for tuberculin skin test reading;
6. Routine care.
Outcomes Return for tuberculin skin test reading within 96 hours
Notes Trial location: Long Beach, California, USA
Setting: urban research clinic
Source of funding: National Institute on Drug Abuse (grant RO1-DA08799)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomization not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No omissions from final analysis.
1004 enrolled, ITT analysis.
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
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Malotte 1999
Methods Individually RCT
Duration: September 1995 to September 1997
Participants Number enrolled: 1078
Inclusion criteria: injection drug and crack cocaine users who had tuberculin skin tests
and were required to return for the reading (age restrictions not specifically stated but
all participants were over age of 18 years)
Exclusion criteria: participation in group’s previous studies
Interventions 1. USD 10 on return for TB skin test reading;
2. Grocery store coupons worth USD 10 on return for TB skin test reading;
3. Patient’s choice of bus passes or coupons for fast food restaurant worth USD 10
on return for TB skin test reading;
4. Motivational education session of 5 to 10 minutes;
5. Routine care.
Outcomes Return for TB skin test reading within 96 hours
Notes Study was a follow-up to Malotte 1998 - trial authors wanted to test effectiveness of
non-cash incentives, as they felt health departments might object to giving cash out to
patients as this was considered controversial
Trial location: Long Beach, California, USA
Setting: urban research clinic
Source of funding: National Institute on Drug Abuse (grant RO1-DA08799)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No description of method of randomiza-
tion.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Noomissions fromfinal analysis. 1078 ran-
domized, ITT analysis
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
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Malotte 2001
Methods Individually RCT
Duration: April 1994 to September 1997 (recruitment period)
Participants Number enrolled: 169
Inclusion criteria: injection drug or crack cocaine users, needing INH treatment for TB
prophylaxis
Exclusion criteria: active TB or medical contraindications to the use of isoniazid
Interventions 1. Twice weekly directly observed therapy (DOT) by study outreach worker at
location chosen by patient, plus USD 5 per visit;
2. Twice weekly DOT by study outreach worker at location chosen by patient;
3. Twice weekly DOT at study site plus USD 5 per visit.
Participants in both arms received INH prophylaxis.
Outcomes Completion of course of INH (6 months if patient HIV negative, 12 months if patient
HIV positive). Also percentage of medications taken on time (all doses in all arms were
directly observed)
Notes Trial location: Long beach, California, USA
Setting: urban research clinic
Source of funding: National Institute on Drug Abuse (grant RO1-DA08799)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization in blocks of 18, assumed to
have been done by computer
Allocation concealment (selection bias) Low risk Allocationwas kept in “numbered, opaque,
sealed envelopes” and “staff ...were unaware
of block size”
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 169 patients randomized. Six excluded
from analysis for medical reasons which
were unlikely to have been related to the
study outcome. ITT analysis
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
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Martins 2009
Methods Individually RCT conducted at three sites in Dili, Timor Leste
Duration: enrolment 16 March to 9 November 2005; follow-up continued until July
2006
Participants Patients with newly diagnosed pulmonary TB, both positive and negative results on
sputum tests
Eligible: 833 (563 excluded)
Randomized: 270 (133 control, 137 intervention group)
Most participants were poor, malnourished men living close to the clinics
Interventions 1. Nutritious, culturally appropriate daily meal (weeks 1 to 8) and food packages
(weeks 9 to 32);
2. Control group given nutritional advice.
Both groups received standard TB treatment
Outcomes Primary outcomes: completion of treatment, including cure
Secondary outcomes: adherence to treatment, weight gain, and clearance of sputum
smears
Notes Outbreak of civil conflict in the country three months before completion of study dis-
rupted service delivery and access of patients to health care (70% of the population
were displaced). However, it is likely that this affected intervention and control groups
similarly
Most participants were poor and malnourished men who lived close to the clinics and
this may limit the external generalizability of the study
Substantial missing data for intermediate outcomes implies that participants did not
attend clinics regularly. Also, intervention was not well received by many participants as
it was inconvenient to attend the clinics at midday for the meal (this was also the reason
for a high number of patients’ refusal to participate in the trial). 70% of participants
had negative smear results, which means that cure could not be objectively verified.
Adherence was not objectively assessed
Adverse events: None necessitated stopping treatment. Itch with or without rash was
more than twice as likely to occur in the intervention group (RR 2.27, 95% CI 1.20 to
4.26)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer generated random allocation se-
quence with randomly varying block sizes
(done by independent statistician using
STATA). Allocation was stratified by com-
munity health clinic and by diagnosis of
TB (positive or negative smear)
Allocation concealment (selection bias) Low risk Concealed from all investigators with se-
quentially numbered opaque sealed en-
velopes prepared distant from study site
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Martins 2009 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Blinding of participants and treatment
providers not done, but independent ob-
server who determined the primary out-
come was blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants received allocated inter-
vention and loss to follow-up (transfer to
another clinic during treatment) was very
small (1% in intervention group and 4%
in control group). ITT analysis
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Unclear risk Two important factors affected the conduct
of the trial and undermined the potential
effectiveness of the intervention. The first
was civil conflict that arose during the last
few months of the trial, resulting in the
displacement of approximately 70% of the
local population, and dramatically increas-
ing the rate of default from treatment. The
second factor was the timing of the provi-
sion of meals to patients in the intervention
group. Many patients found the provision
of meals, together with treatment, at mid-
day inconvenient, and this may have be-
come a barrier to adherence to treatment
Morisky 2001
Methods Individually RCT.
Duration: not stated
Participants Number enrolled: 794
Inclusion criteria: adolescents aged 11 to 19 years who needed treatment for latent TB
infection
Exclusion criteria: not stated
Interventions 1. Peer counselling (at least once every two weeks);
2. Incentive (participant-parent contingency contract, where parent and patient
negotiated a reward for adherence to treatment. This was provided by the parent and
given at a frequency negotiated by the parent and participant). Examples of incentives
included a special meal at home, going out to eat, clothing, going to movies or renting
a video, or anything agreeable to both parent and adolescent;
3. Combined peer counselling and incentive (participant-parent contingency
contract);
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Morisky 2001 (Continued)
4. Usual care.
Participants in intervention and control arms received INH prophylaxis
Outcomes Completion of 6 months of INH prophylaxis; measured using the discharge summary
recorded in the patient’s medical chart
Notes Trial location: Los Angeles County, USA
Setting: urban community based clinics
Source of funding: National Heart, Lung and Blood Institute (ROI-55770)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described.
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Authors state that ITT model was used (pg
570). 794 adolescents enrolled and analysed.
No omissions from final analysis
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is no
earlier methods paper listing the pre-specified
outcomes
Other bias Low risk Over and above the interventions described
above, patients were interviewed three times
during the study and at each interview re-
ceivedUSD15. The additional interest in the
participants, plus the cash which may have
acted as a further incentive to adhere, may
be regarded as interventions in themselves.
However, this applied to all participants and
would not have introduced bias
Pilote 1996
Methods Individually RCT
Duration: June 1992 to April 1994
Participants Number enrolled: 244
Inclusion criteria: Homeless “men and women”, age not specified (but all over 18 years
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Pilote 1996 (Continued)
in results), who had a tuberculin skin test and were required to attend a clinic to initiate
treatment for latent or active TB
Exclusion criteria: Recent investigation for TB
Interventions 1. Peer health advisers plus usual care (advisers accompanied patients to clinics and
assisted with filling out forms etc);
2. Incentive of USD 5 cash if participant came to clinic within 3 weeks of
randomization plus usual care;
3. Usual care (appointment at TB clinic plus a bus token for transport to clinic).
Outcomes Attendance at clinic appointment within three weeks of positive reading of tuberculin
skin test
Notes Second phase of this study reported in Tulsky et al 2000.
Trial location: San Fransisco, California, USA
Setting: urban community based TB clinic (attached to San Francisco General Hospital)
Source of funding: Kaiser Family Foundation, Acquired Immunodeficiency Syndrome
Clinical Research Center, San Francisco, California; Universitywide Acquired Immun-
odeficiency Syndrome Research
Program, University of California; and by grant R01-DA04363-07 from the National
Institute on Drug Abuse, Bethesda, MD
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “treatment group was assigned by sampling
without replacement from blocks of nine”.
Assumed to be done by computer
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 244 patients randomized, 244 analysed.
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
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Tulsky 2000
Methods Individually RCT
Duration: June 1992 to May 1995 (recruitment period June 1992 to December 1994,
plus 6 months of patient follow-up time)
Participants Number enrolled: 118
Inclusion criteria: homeless adults, with positive tuberculin skin test or credible history
of prior positive tuberculin skin test but no follow-up for this in the 6 months prior to
the study
Exlusion criteria: receiving treatment or prophylaxis for TB at the time of the study, or
HIV positive
Interventions 1. Usual care (self-supervised daily dosing with INH and monthly clinic visits for
assessment and refill of tablets);
2. Taking of 900 mg INH directly observed at each of two weekly visits to study site;
plus an incentive of USD 5 cash;
3. Peer health advisor (who directly supervised taking of treatment twice weekly,
accompanied patient to clinic and looked for the patient if lost to follow-up).
Participants in intervention and control arms received INH prophylaxis
Outcomes Completion of 6 months of INH preventive treatment as documented in patients’ clinic
charts; number of months of INH dispensed
Notes Trial location: San Francisco, California, USA
Setting: community-based TB clinic
Source of funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization used, therefore allo-
cation sequence assumed to have been gen-
erated by computer
Allocation concealment (selection bias) Unclear risk Not described.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 330 patients randomized, 195 found to
require further evaluation and 37 needed
further diagnostic tests (sputum cultures
and liver function tests). Of 121 who were
prescribed INH, 118were analysed - 3were
excluded from study because of “toxic ef-
fects of INH”. These reasons unlikely to be
related to final outcome
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Tulsky 2000 (Continued)
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
Tulsky 2004
Methods Individually RCT.
Duration: May 1996 to May 1998 (based on recruitment period of May 1996 to De-
cember 1997, plus 6 months for patient follow-up)
Participants Number enrolled: 119 (85% male; median age 41 years, range 21 to 79)
Inclusion criteria: homeless adults who were eligible for preventive TB treatment. Adults
who were “truly homeless” (living in street and shelter dwellings) and those who were
“marginally housed” (living in residential hotels) were recruited into the study
Exclusion criteria: active TB or HIV positive
Interventions 1. USD5 cash incentive for each twice weekly appointment kept;
2. Non-cash incentive with face value of USD 5 for each twice weekly appointment
kept (patients could choose between fast food or grocery store coupons, phone cards or
bus tokens).
Participants in intervention and control arms received INH prophylaxis
Outcomes 1. Completion of preventive treatment (assessed by reviewing TB clinic records);
2. Length of time needed to look for participants who had missed scheduled
appointments and didn’t respond to letters or phone calls. (A tracking form including
names and mailing addresses of family, friends, and case workers was completed for
each participant. After the first missed appointment, staff made phone calls and sent
reminder letters. If the participant did not attend the next scheduled visit, outreach
efforts were initiated and were guided by the information on the tracking form).
Notes As the cash incentive arm did so much better than the non incentive arm in the study
performed by this group previously (Tulsky 2000), the trial authors felt it would be
unethical to continue to randomize one group to no incentive
Trial location: San Francisco, California, USA
Setting: urban, community-based TB clinic
Source of funding: National Heart, Lung, and Blood Institute (grant HL55729) and the
National Institute of Mental Health (grant MH54907)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence was generated “...from a list of
randomly generated numbers”
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Tulsky 2004 (Continued)
Allocation concealment (selection bias) Unclear risk “...numbers previously sealed into individ-
ual envelopes and selected in consecutive
order”. Unclear if these envelopes were
opaque
Blinding (performance bias and detection
bias)
All outcomes
Low risk “TB clinic physicians were blinded with re-
spect to the results of the randomisation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 141 patients randomized but 16 not pre-
scribed INH (4 in cash incentive arm, 12
in non-cash incentive arm). Reasons for ex-
clusion clinical and unlikely to be related to
allocation. 6 patients censored (5 for clin-
ical reasons, 1 because died in hotel fire).
Again, reasons for exclusion unlikely to be
related to allocation or outcome. 119 pa-
tients analysed
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias High risk The study groups were not the same with
respect to their primary housing in the year
prior to the study. In the cash incentive arm,
23% had lived in a shelter or on the street,
whilst 41% of the non-cash incentive arm
had done so
White 1998
Methods Individually RCT
Duration: one year (1996)
Participants Number enrolled: 79 (98% male, mean age 32.0 years)
Inclusion criteria: jail inmates eligible for INH prophylaxis for latent TB infection
Exclusion criteria: unable to speak English or Spanish, or sequestration from jail popu-
lation due to violence or mental illness
Interventions 1. Promise of USD 5 cash incentive (to be provided) on making first visit to
community TB clinic to continue INH prophylaxis after release from jail plus
standardised TB education;
2. Standardised TB education (about TB and the importance of taking INH
prophylaxis).
Participants in intervention and control arms received INH prophylaxis
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White 1998 (Continued)
Outcomes Attendance at first visit to community TB clinic to continue INH prophylaxis after
release from jail
Notes Trial location: San Francisco, California, USA
Setting: Prison
Source of funding: Academic Senate of the University of California, San Francisco
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization done using table of ran-
dom numbers.
Allocation concealment (selection bias) Low risk Previously sealed, ordered, opaque en-
velopes used.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Research assistants collecting clinic data (as
to whether participant attended first ap-
pointment or not) were blinded as to par-
ticipants’ assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of the 79 inmates enrolled in the study,
18 remained in prison for the full dura-
tion of their INH treatment (and so were
never required to present at a community
TB clinic). 61 were analysable, and there
were no differences between treatment allo-
cations in this group. “Data were rechecked
for internal validity and there were no dif-
ferences by study group in any of the vari-
ables collected for this analytic sample of
61 persons” (pg 508)
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
Other bias Low risk The study appears to be free of other bias.
White 2002
Methods Individually RCT
Duration of enrolment: 1 March 1998 to 31 May 1999
Participants Number enrolled: 558 (82% male; median age 28.5 years in incentive arm, 29.7 years
in routine care arm, and 29.5 years in education arm)
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White 2002 (Continued)
Inclusion criteria: Jail inmates with latent TB infection, eligible for and agreeable to INH
prophylaxis
Exclusion criteria: HIV positive, not able to speak English or Spanish, assessed by Sher-
riff ’s personnel to be violent, or by mental health staff to have a serious psychiatric illness
Interventions 1. Promise of incentive (USD 25 equivalent in food or transportation vouchers),
provided at the first visit to the community TB clinic after release from jail;
2. Education, provided every two weeks whilst in jail;
3. Usual care (neither intervention).
Outcomes 1. Attendance at first visit to community TB clinic to continue INH prophylaxis
within one month after release from jail;
2. Completion of full course of INH treatment.
Notes HIVpositive patients on INHprophylaxis receive very different programmeof treatment,
including incentives
Trial location: San Francisco, California, USA
Setting: prison
Source of funding: National Institute of Nursing Research, National Institutes of Health,
Bethesda, Md. (grant R01 NR04456)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization done using table of ran-
dom numbers.
Allocation concealment (selection bias) Low risk Ordered, opaque, sealed envelopes used.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Research assistants collecting clinic data (as
to whether participant attended first ap-
pointment or not) were blinded as to par-
ticipants’ assignments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Of 558 inmates enrolled, 48 discontinued
INH treatment whilst in jail, and 185 com-
pleted INH treatment whilst in jail. Thus
325 were eligible for analysis. There were
no differences between study group in ei-
ther the 325 analysable patients or 558 ini-
tially enrolled patients. Reasons for exclu-
sion from analysis not likely to be related
to final outcome. ITT analysis for those re-
leased while taking INH
Selective reporting (reporting bias) Unclear risk Study protocol not available and there is
no earlier methods paper listing the pre-
specified outcomes
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White 2002 (Continued)
Other bias Low risk The study appears to be free of other bias.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cantalice Filho 2009 Not a RCT; essentially two cross-sectional studies where first group was not given incentive and second group
was
Cheng 1997 Not a RCT, as allocation to treatment interventions was done by day of the week
Chua 2015 Not a RCT; allocation to receive the grocery voucher intervention was not randomized
FitzGerald 1999 Not a RCT; essentially two cross-sectional studies where first group was not given incentive and second group
was
Gärden 2013 Not a RCT; comparison group was an historical control.
Jahnavi 2010 A trial of community health worker delivered TB treatment combined with food supplements; and not a trial
of food incentives per se
Morisky 1990 Not a RCT, as allocation to treatment interventions was done by the last digits of the participants’ clinic
numbers
Nyamathi 2006 Both the intervention and control arms received a USD 5 cash incentive for each dose of INH prophylaxis
taken. It was therefore not possible to assess the effect of the incentive in this study. The main intervention
was a nurse case management programme
Yao 2008 Controlled before-and-after study, with no evidence of randomization to control or intervention groups.
Incentives were provided to health care workers as well as patients, and the effect of patients’ incentives only
was not disaggregated
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D A T A A N D A N A L Y S E S
Comparison 1. Incentive versus routine care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Treatment success (completion
or cure)
2 4356 Risk Ratio (Fixed, 95% CI) 1.04 [0.97, 1.13]
2 Completion of TB prophylaxis 3 Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Clinic visit to start or continue
TB prophylaxis
3 595 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [1.27, 1.96]
4 Return for tuberculin skin test
results
2 1371 Risk Ratio (M-H, Random, 95% CI) 2.16 [1.41, 3.29]
Comparison 2. Immediate versus deferred incentive
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Completion of TB prophylaxis 1 300 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.98, 1.24]
Comparison 3. Cash incentive versus non-cash incentive
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Completion of TB prophylaxis 1 141 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.02, 1.56]
2 Return for tuberculin skin test
reading
1 652 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [1.07, 1.19]
Comparison 4. Incentives versus any other intervention
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Completion of TB prophylaxis 3 837 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.59, 1.83]
2 Clinic visit to start or continue
TB prophylaxis
2 535 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.92, 1.31]
3 Return for tuberculin skin
testing
2 1366 Risk Ratio (M-H, Random, 95% CI) 2.16 [1.56, 3.00]
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Comparison 5. Different values of cash incentive
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Return for tuberculin skin test
reading
1 404 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [1.01, 1.16]
Analysis 1.1. Comparison 1 Incentive versus routine care, Outcome 1 Treatment success (completion or
cure).
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 1 Incentive versus routine care
Outcome: 1 Treatment success (completion or cure)
Study or subgroup Incentives Control log [Risk Ratio] Risk Ratio Weight Risk Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Lutge 2013 2107 1984 0.074549 (0.047377) 66.9 % 1.08 [ 0.98, 1.18 ]
Martins 2009 136 129 -0.0202 (0.067386) 33.1 % 0.98 [ 0.86, 1.12 ]
Total (95% CI) 2243 2113 100.0 % 1.04 [ 0.97, 1.13 ]
Heterogeneity: Chi2 = 1.32, df = 1 (P = 0.25); I2 =24%
Test for overall effect: Z = 1.11 (P = 0.26)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours control Favours incentive
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Analysis 1.2. Comparison 1 Incentive versus routine care, Outcome 2 Completion of TB prophylaxis.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 1 Incentive versus routine care
Outcome: 2 Completion of TB prophylaxis
Study or subgroup Any incentive Routine care Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Malotte 2001 28/53 2/55 14.53 [ 3.64, 57.98 ]
Morisky 2001 152/199 147/189 0.98 [ 0.88, 1.09 ]
White 2002 26/185 26/188 1.02 [ 0.61, 1.68 ]
0.01 0.1 1 10 100
Favours routine care Favours incentive
Analysis 1.3. Comparison 1 Incentive versus routine care, Outcome 3 Clinic visit to start or continue TB
prophylaxis.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 1 Incentive versus routine care
Outcome: 3 Clinic visit to start or continue TB prophylaxis
Study or subgroup Any incentive Routine care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pilote 1996 69/82 42/79 57.3 % 1.58 [ 1.26, 1.99 ]
White 1998 8/31 7/30 9.5 % 1.11 [ 0.46, 2.67 ]
White 2002 42/185 25/188 33.2 % 1.71 [ 1.09, 2.68 ]
Total (95% CI) 298 297 100.0 % 1.58 [ 1.27, 1.96 ]
Total events: 119 (Any incentive), 74 (Routine care)
Heterogeneity: Chi2 = 0.74, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 4.16 (P = 0.000032)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours routine care Favours incentive
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Analysis 1.4. Comparison 1 Incentive versus routine care, Outcome 4 Return for tuberculin skin test results.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 1 Incentive versus routine care
Outcome: 4 Return for tuberculin skin test results
Study or subgroup Any incentive Routine care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Malotte 1998 361/404 33/100 45.8 % 2.71 [ 2.04, 3.59 ]
Malotte 1999 572/652 106/215 54.2 % 1.78 [ 1.55, 2.04 ]
Total (95% CI) 1056 315 100.0 % 2.16 [ 1.41, 3.29 ]
Total events: 933 (Any incentive), 139 (Routine care)
Heterogeneity: Tau2 = 0.08; Chi2 = 7.29, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 3.57 (P = 0.00035)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours routine care Favours incentive
Analysis 2.1. Comparison 2 Immediate versus deferred incentive, Outcome 1 Completion of TB
prophylaxis.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 2 Immediate versus deferred incentive
Outcome: 1 Completion of TB prophylaxis
Study or subgroup Immediate incentive Deferred incentive Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chaisson 2001 126/152 111/148 100.0 % 1.11 [ 0.98, 1.24 ]
Total (95% CI) 152 148 100.0 % 1.11 [ 0.98, 1.24 ]
Total events: 126 (Immediate incentive), 111 (Deferred incentive)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours deferred Favours immediate
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Analysis 3.1. Comparison 3 Cash incentive versus non-cash incentive, Outcome 1 Completion of TB
prophylaxis.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 3 Cash incentive versus non-cash incentive
Outcome: 1 Completion of TB prophylaxis
Study or subgroup Cash incentive Non-cash incentive Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Tulsky 2004 58/72 44/69 100.0 % 1.26 [ 1.02, 1.56 ]
Total (95% CI) 72 69 100.0 % 1.26 [ 1.02, 1.56 ]
Total events: 58 (Cash incentive), 44 (Non-cash incentive)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours non-cash Favours cash incentive
Analysis 3.2. Comparison 3 Cash incentive versus non-cash incentive, Outcome 2 Return for tuberculin skin
test reading.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 3 Cash incentive versus non-cash incentive
Outcome: 2 Return for tuberculin skin test reading
Study or subgroup Cash incentive Non-cash incentive Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Malotte 1999 206/217 366/435 100.0 % 1.13 [ 1.07, 1.19 ]
Total (95% CI) 217 435 100.0 % 1.13 [ 1.07, 1.19 ]
Total events: 206 (Cash incentive), 366 (Non-cash incentive)
Heterogeneity: not applicable
Test for overall effect: Z = 4.63 (P < 0.00001)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours non-cash Favours cash incentive
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Analysis 4.1. Comparison 4 Incentives versus any other intervention, Outcome 1 Completion of TB
prophylaxis.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 4 Incentives versus any other intervention
Outcome: 1 Completion of TB prophylaxis
Study or subgroup Incentive
Any other
interven-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Morisky 2001 152/199 151/188 45.1 % 0.95 [ 0.86, 1.06 ]
Tulsky 2000 19/43 7/37 25.5 % 2.34 [ 1.11, 4.93 ]
White 2002 14/185 24/185 29.4 % 0.58 [ 0.31, 1.09 ]
Total (95% CI) 427 410 100.0 % 1.04 [ 0.59, 1.83 ]
Total events: 185 (Incentive), 182 (Any other intervention)
Heterogeneity: Tau2 = 0.18; Chi2 = 7.90, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 0.12 (P = 0.90)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours other Favours incentive
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Analysis 4.2. Comparison 4 Incentives versus any other intervention, Outcome 2 Clinic visit to start or
continue TB prophylaxis.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 4 Incentives versus any other intervention
Outcome: 2 Clinic visit to start or continue TB prophylaxis
Study or subgroup Incentive
Any other
interven-
tion Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pilote 1996 69/82 62/83 60.6 % 1.13 [ 0.96, 1.32 ]
White 2002 42/185 40/185 39.4 % 1.05 [ 0.72, 1.54 ]
Total (95% CI) 267 268 100.0 % 1.10 [ 0.92, 1.31 ]
Total events: 111 (Incentive), 102 (Any other intervention)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.31)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Favours other Favours incentive
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Analysis 4.3. Comparison 4 Incentives versus any other intervention, Outcome 3 Return for tuberculin skin
testing.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 4 Incentives versus any other intervention
Outcome: 3 Return for tuberculin skin testing
Study or subgroup Incentive
Any other
interven-
tion Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Malotte 1998 361/404 34/99 43.8 % 2.60 [ 1.98, 3.42 ]
Malotte 1999 572/652 99/211 56.2 % 1.87 [ 1.62, 2.16 ]
Total (95% CI) 1056 310 100.0 % 2.16 [ 1.56, 3.00 ]
Total events: 933 (Incentive), 133 (Any other intervention)
Heterogeneity: Tau2 = 0.04; Chi2 = 4.50, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 4.62 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours other Favours incentive
Analysis 5.1. Comparison 5 Different values of cash incentive, Outcome 1 Return for tuberculin skin test
reading.
Review: Incentives and enablers to improve adherence in tuberculosis
Comparison: 5 Different values of cash incentive
Outcome: 1 Return for tuberculin skin test reading
Study or subgroup $10 cash incentive $5 cash incentive Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Malotte 1998 186/200 175/204 100.0 % 1.08 [ 1.01, 1.16 ]
Total (95% CI) 200 204 100.0 % 1.08 [ 1.01, 1.16 ]
Total events: 186 ($10 cash incentive), 175 ($5 cash incentive)
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours $5 incentive Favours $10 incentive
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A D D I T I O N A L T A B L E S
Table 1. Detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb SCI-
EXPANDED
and SSC
1 tuberculosis tuberculosis tuberculosis tuberculosis tuberculosis tuberculosis
2 adherence PATIENT
COMPLIANCE
PATIENT
COMPLIANCE
PATIENT-
COMPLIANCE
adherence adherence
3 compliance PATIENT
DROPOUTS
PATIENT
DROPOUTS
TREATMENT-
REFUSAL
compliance compliance
4 Monitor* MOTIVATION MOTIVATION MOTIVATION Monitor$ Monitor*
5 Incentive* SOCIAL
SUPPORT
SOCIAL
SUPPORT
SOCIAL
SUPPORT
Incentive$ Incentive*
6 Reward* CONTRACTS CONTRACTS COMPENSA-
TION
Reward$ Reward*
7 Voucher* Adherence Adherence Adherence Voucher$ Voucher*
8 Payment* Incentive* Incentive* Incentive$ Payment$ Payment*
9 Reimbursement* Reward* Reward* Reward$ Reimbursement$ Reimbursement*
10 Concordance Voucher* Voucher* Voucher$ Concordance Concordance
11 Cash transfer* Payment* Payment* Payment$ Cash transfer$ Cash transfer*
12 2-11/OR Reimbursement* Reimbursement* Reimbursement$ 2-11/OR 2-11/OR
13 1 AND 12 Concordance Concordance Concordance 1 AND 12 1 AND 12
14 - Cash transfer* Cash transfer* Cash transfer$ - -
15 - 2-14/OR 2-14/OR 2-14/OR - -
16 - 1 AND 15 1 AND 15 1 AND 15 - -
17 - - Limit 16 to Hu-
man
Limit 16 to Hu-
mans
- -
aCochrane Infectious Diseases Group Specialized Register.
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bSearch terms used in combination with the search strategy for retrieving trials developed by Cochrane (Lefebvre 2011); Upper case:
MeSH or EMTREE heading; Lower case: free text term.
A P P E N D I C E S
Appendix 1. Summary of findings table 2
Immediate versus deferred incentive for improving patient adherence to TB management
Patient or population: people at high risk of developing TB
Settings: high- and low-income settings
Intervention: immediate incentive (received on a regular basis during treatment)
Comparison: deferred incentive (received only at end of treatment).
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Deferred incentive Immediate
Completion of TB
prophylaxis
750 per 1000 832 per 1000
(735 to 930)
RR 1.11
(0.98 to 1.24)
300
(1 trial)
⊕⊕©©
low1,2
The assumed risk is taken from the control group in the trial. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for indirectness: this trial was conducted in specific subpopulations from the USA and the result may not be
applicable to other settings.
2Downgraded by 1 for imprecision: the 95% CI of the estimate of effect includes both clinically important benefit and no effect.
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Appendix 2. Summary of findings table 3
Cash versus non-cash incentive for improving patient adherence to TB management
Patient or population: people at high risk of developing TB
Settings: high- and low-income settings
Intervention: cash incentive
Comparison: non-cash incentive
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
Non-cash incentive Cash
Return
for tuberculin skin
test reading
841 per 1000 950 per 1000
(900 to 992)
RR 1.13
(1.07 to 1.18)
652
(1 trial)
⊕⊕©©
low1
Completion of TB
prophylaxis
638 per 1000 804 per 1000
(651 to 995)
RR 1.26
(1.02 to 1.56)
141
(1 trial)
⊕⊕©©
low1
The assumed risk is taken from the control group in the trial. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 2 for indirectness: these trials were conducted in specific subpopulations from the USA and the results may not be
applicable to other settings.
Appendix 3. Summary of findings table 4
Comparison of different values of cash incentives for improving patient adherence to TB management
Patient or population: people at high risk of developing TB
Settings: high- and low-income settings
Intervention: higher cash value (USD 10)
Comparison: lower cash value (USD 5)
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(Continued)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
lower cash value higher cash value
Return
for tuberculin skin
test reading
858 per 1000 927 per 1000
(867 to 995)
RR 1.08
(1.01 to 1.16)
404
(1 trial)
⊕⊕©©
low1
The assumed risk is taken from the control group in the trial. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 2 for indirectness: one trial conducted in a specific subpopulation from the USA and the result may not be applicable
to other settings.
Appendix 4. Summary of findings table 5
Incentives versus educational or motivational interventions for improving patient adherence to anti-TB treatment
Patient or population: patients at high risk of developing TB
Settings: high- and low-income settings
Intervention: an incentive
Comparison: any educational or motivational intervention
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(trials)
Quality of the evi-
dence
(GRADE)
Assumed risk Corresponding
risk
any other interven-
tion
material incentives
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(Continued)
Return
for tuberculin skin
test reading
429 per 1000 927 per 1000
(669 to 1000)
RR 2.16
(1.56 to 3.00)
1366
(2 trials)
⊕⊕©©
low1,2
Return to clinic to
start or continue
treatment
381 per 1000 419 per 1000
(351 to 499)
RR 1.10
(0.92 to 1.31)
535
(2 trials)
⊕⊕©©
low2,3
Completion of
prophylaxis for la-
tent TB
444 per 1000 462 per 1000
(262 to 813)
RR 1.04
(0.59 to 1.83)
837
(3 trials)
⊕⊕©©
low2,4
The assumed risk is taken from the control group in the trial. The corresponding risk (and its 95% CI) is based on the assumed
risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1Downgraded by 1 for risk of bias: neither study adequately described the method of randomization.
2Downgraded by 1 for indirectness: these trials were conducted in specific subpopulations from the USA and the result may not be
applicable to other settings.
3Downgraded by 1 for imprecision: the 95% CI includes what may be clinically important benefits and no effect.
4Downgraded by 1 for inconsistency: two studies found no suggestion of a benefit with the incentive, and just one study found a
clinically and statistically significant benefit in drug users.
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